
The FDA has authorized Visby Medical's at-home test for chlamydia, gonorrhea, and trichomoniasis, marking a major advancement in sexual health testing accessibility.

Roche's investigational obesity drug CT-388 demonstrated 22.5% placebo-adjusted weight loss at 48 weeks in Phase 2 trial, advancing to Phase 3 studies.